Do Meu Jeito

Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases

Retrieved on: 
Thursday, September 7, 2023
OrbiMed, Obesity, Heart failure, Do Meu Jeito, USD, Doctor of Philosophy, Sarcopenia, Science, MD, Patient, Mortality, Cardiology, Pharmaceutical industry, Dietary supplement, Sanofi

The oversubscribed financing was co-led by new investors Jeito and Orbimed, with participation from existing investors Kurma Partners, Fountain Healthcare Partners, V-Bio Ventures, Invivo Capital, and Omnes Capital.

Key Points: 
  • The oversubscribed financing was co-led by new investors Jeito and Orbimed, with participation from existing investors Kurma Partners, Fountain Healthcare Partners, V-Bio Ventures, Invivo Capital, and Omnes Capital.
  • Corteria was founded in 2021 by Sanofi’s former head of cardiovascular research, Philip Janiak and Marie-Laure Ozoux, former cardiovascular project leader at Sanofi, around two cardiovascular programs in-licensed from Sanofi2.
  • Proceeds from the financing will be used to advance the Company’s heart failure pipeline into the clinic.
  • Andreas Wallnoefer, Partner at Jeito Capital and with strong industry experience in the cardiovascular field, will join Corteria’s Board of Directors.

Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis

Retrieved on: 
Thursday, April 13, 2023
Partnership, Hereditary diffuse gastric cancer, INSERM, Cancer, T cell, Do Meu Jeito, Antibody, Doctor of Philosophy, Lung, Fibrosis, Novo Holdings A/S, MD, Patient, Biology, ADC, Growth, R, Phase, Claudin, Therapy, Pharmaceutical industry, CLDN1

The financing was led by Jeito together with Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital.

Key Points: 
  • The financing was led by Jeito together with Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital.
  • Funds will also be used to develop the Company’s platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodies.
  • Jeito became a key investor in Alentis as part of a $67 million Series B financing in June 2021.
  • Dr. Roberto Iacone, CEO at Alentis Therapeutics, said: “We are absolutely delighted with this support from our investors.

Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders

Retrieved on: 
Tuesday, March 7, 2023
Depression, Doctor of Philosophy, Growth, Tourette syndrome, Polaris Partners, Binge eating disorder, INVU (song), CHF, Safety, Trigeminal neuralgia, Tuberous sclerosis complex tumor suppressors, CNS, Knowledge, Capital, Face, Seizure, DSM-IV codes, Drug development, Patient, Sofinnova, News, Central nervous system disease, Do Meu Jeito, MD, Acceleration, UPMC, Fine chemical, Pharmaceutical industry, Noema

USD 112 million) financing in Noema Pharma (the “Company”), a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders.

Key Points: 
  • USD 112 million) financing in Noema Pharma (the “Company”), a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders.
  • As part of its indication expansion strategy, the Company also anticipates initiating clinical development in Atypical Depression and Binge Eating Disorders.
  • Jeito selected Noema Pharma in line with its investment strategy of supporting the development of the most promising European biopharma companies with high growth and acceleration potential.
  • This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing

Retrieved on: 
Tuesday, December 6, 2022
Asthma, Private equity, Pulmonology, United, Triazole, Mortality, Cystic fibrosis, Incidence, Series, Aspergillosis, Do Meu Jeito, Oxygen toxicity, Chronic pulmonary aspergillosis, Doctor of Philosophy, Critical care, Cystic Fibrosis Foundation, MD, Azole, Chronic obstructive pulmonary disease, Disease, Immunodeficiency, IP Group, Lung, Allergic bronchopulmonary aspergillosis, Growth, IPA, Investment, Risk, Respiratory disease, Patient, Pharmaceutical industry, Pulmocide, Aspergillus

Jeito previously led an oversubscribed $92 million raise in Pulmocide, and has since provided continuous support to the Company in line with its unique investment strategy.

Key Points: 
  • Jeito previously led an oversubscribed $92 million raise in Pulmocide, and has since provided continuous support to the Company in line with its unique investment strategy.
  • Jeito’s further investment in Pulmocide demonstrates our commitment to support the most innovative biopharmaceutical companies and accelerate the development of much-needed treatments for patients.
  • Jeito Capital has €534 million under management and a rapidly growing portfolio of investments.
  • A late-stage clinical program has been initiated to support registration in patients who have failed prior therapy for IPA.

Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics

Retrieved on: 
Tuesday, November 29, 2022
Growth, AstraZeneca, Doctor of Philosophy, Kite Pharma, Private equity, Netherlands Cancer Institute, TPG, TP53, Cell, KRAS, Partnership, Patient, Do Meu Jeito, Arm, Polaris Partners, Protein, Investment, Cancer, TCR, Entrepreneurship, Acquisition, Pharmaceutical industry, Vaccine, Management, Medical imaging, MD, Neogene, EU

Paris, France, November 29th2022 - Jeito Capital ("Jeito"), the largest fully independent international private equity firm dedicated to healthcare and biopharma, is pleased to announce the realization of its investment in Neogene Therapeutics, Inc. (Neogene Therapeutics or Neogene) to AstraZeneca a global, science-led biopharmaceutical company.

Key Points: 
  • Paris, France, November 29th2022 - Jeito Capital ("Jeito"), the largest fully independent international private equity firm dedicated to healthcare and biopharma, is pleased to announce the realization of its investment in Neogene Therapeutics, Inc. (Neogene Therapeutics or Neogene) to AstraZeneca a global, science-led biopharmaceutical company.
  • Neogene is a global clinical-stage company pioneering the discovery, development, and manufacturing of next-generation T cell receptor therapies (TCR-Ts).
  • Jeito co-led Neogenes $110 million Series A financing marking the first investment since the launch of the fund.
  • Since Jeitos investment, Neogene has become a clinical stage company, and expanded both its pipeline of next-generation TCR-Ts and its manufacturing capabilities.

Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer

Retrieved on: 
Tuesday, November 22, 2022
Growth, Doctor of Philosophy, Immune system, Acceleration, Capital, Patient, Neoplasm, Tumor microenvironment, MD, NK, EUR, Cancer, B cell, Research, Immunotherapy, Investment, Pharmaceutical industry, Vaccine, Renewable energy, Do Meu Jeito

Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer

Key Points: 
  • Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
    CatalYm is developing a new class of anti-cancer immunotherapies, which have already demonstrated initial promising clinical results in advanced-stage solid tumor patients
    Paris, France, November 22nd2022 - Jeito Capital ("Jeito"), a leading independent international private equity firm dedicated to healthcare and biopharma, announced today that it has co-led a EUR 50 million Series C financing round in CatalYm, a clinical-stage biopharmaceutical company developing novel immunotherapies to fight cancer.
  • It is currently in Phase 2 clinical studies in patients with solid tumors that are relapsed/refractory to prior anti-PD1/-PD-L1 treatment.
  • Proceeds from the financing will primarily be used to expand the Phase 2 clinical development program of visugromab.
  • With CatalYm, Jeito makes its first investment in Germany, which has a very dynamic and internationally recognized biopharma ecosystem.

CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors

Retrieved on: 
Tuesday, November 22, 2022
Pharmaceutical, Health, Oncology, Clinical Trials, Immunotherapy, Investment, EUR, Neoplasm, Series, NK, Cancer, USD, Research, Immune system, Tumor microenvironment, B cell, Do Meu Jeito, Invention, Immunosuppression, Growth, Patient, Pharmaceutical industry, Vaccine

CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round.

Key Points: 
  • CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round.
  • The financing will support the continued, promising clinical development of its lead candidate, visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).
  • We deeply value the commitment of our new and existing investors, which will enable further clinical development, moving our lead program towards pivotal studies.
  • Proceeds from the round will fund the expansion of CatalYms visugromab Phase 2 development program.

Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases

Retrieved on: 
Tuesday, November 1, 2022
Monograph, IMD, Growth, CEO, Autoimmunity, Capital, Antibody, Inflammation, Disease, Creativity, ARCH, Cell, Immune system, B cell, Safety, Neutrophil, Investment, Manufacturing execution system, Allergy, Patient, Precision medicine, Therapy, Science, Vaccine, Pharmaceutical industry, Do Meu Jeito

Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases

Key Points: 
  • Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
    Paris, France, November 1st2022 - Jeito Capital ("Jeito"), a leading independent international private equity firm dedicated to biopharma, announced today that it has participated in the $120 million financing of Human Immunology Biosciences (HI-Bio), a clinical-stage biotech company developing targeted therapies for patients suffering from severe immune-mediated diseases (IMD).
  • Jeito Capital joins a syndicate of world class investors including ARCH Venture Partners and Monograph Capital in backing the San Francisco-based company.
  • HI-Bio has multiple clinical-stage programs and a strong translational platform with the potential to address several diseases with unmet medical needs.
  • Few targeted therapies exist for patients affected by IMDs, which include autoimmune, allergic and inflammatory diseases.

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

Retrieved on: 
Wednesday, September 14, 2022
Retinitis pigmentosa, RP, Retina, Outline of health sciences, Foundation Fighting Blindness, Twitter, UPMC, Stargardt disease, CRISPR, University of Pittsburgh School of Medicine, Intellia Therapeutics, LinkedIn, Company, Gene, Growth, Therapy, Severe cognitive impairment, Usher syndrome, Patient, Investment, The New England Journal of Medicine, Cell, Nature, Solution, Foundation, Science, NASDAQ, Do Meu Jeito, Macular degeneration, Research, University, Mutation, Genome, IRDS, Visual impairment, NTLA, Pharmaceutical industry, Lancet

SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.

Key Points: 
  • SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.
  • Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the worlds most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs).
  • The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ: NTLA) to develop novel genome editing-based treatments for ocular diseases utilizing CRISPR-Cas9 technology.
  • Inherited retinal diseases are a group of progressive eye conditions that can cause severe vision loss and, in certain cases, lead to total blindness.

Jeito Capital co-leads €75 million Series B financing in SparingVision

Retrieved on: 
Wednesday, September 14, 2022
Professional Services, Health, Genetics, Finance, Pharmaceutical, Optical, Biotechnology, Retinitis pigmentosa, Retina, Foundation Fighting Blindness, Capital, Private equity, Ophthalmology, Intellia Therapeutics, Company, FFB, Therapy, Patient, Investment, CEO, Technology, Severe cognitive impairment, Foundation, NASDAQ, Genomics, Research, AMD, University, IRDS, NTLA, Pharmaceutical industry, Do Meu Jeito

Jeito Capital ("Jeito"), a leading independent Private Equity firm dedicated to biotech and biopharma, announced today that it has co-led a Series B financing round in SparingVision, a privately held French biotech company.

Key Points: 
  • Jeito Capital ("Jeito"), a leading independent Private Equity firm dedicated to biotech and biopharma, announced today that it has co-led a Series B financing round in SparingVision, a privately held French biotech company.
  • In co-leading this Series B financing, Jeito Capital is demonstrating its commitment to invest significant capital in continuity, throughout the different development stages of a promising biotech company, to build market leaders with accelerated patients access globally, especially in Europe and the United States.
  • Our new investment in SparingVision illustrates perfectly Jeito Capital's mission to build market leaders with global reach to bring ground-breaking therapies to patients with high unmet needs.
  • Sabine Dandiguian, Managing Partner of Jeito, said: We are very pleased to support the success of SparingVision's incredible management team.